Inhaled human insulin

Drugs of Today

Volumn 42, Issue 4, 2006, Pages 207-221

  Strack, Thomas R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ZINC SUSPENSION; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

AEROSOL; ANTIBODY RESPONSE; AREA UNDER THE CURVE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRY POWDER; EXPERIMENTAL MODEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INHALER; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; LUNG FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT SATISFACTION; REVIEW;

ADMINISTRATION, INHALATION; ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NEBULIZERS AND VAPORIZERS; PATIENT COMPLIANCE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33745144972     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.4.977449     Document Type: Review

References (51)

1. Hunt, L.M., Valenzuela, M.A., Pugh, J.A. NID-DM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997, 20: 292-8.
2. Overman, H., Heinemann, L. Injection-meal interval: Recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999, 43: 137-42.
3. Heubner, W., de Jongh, S.E., Laquer, E. Uber inhalation von insulin. Klin Wochenschr 1924, 3: 2342-3 (in German).
4. Gaensslen, M. Uber inhalation von insulin. Klin Wochenschr 1925, 4: 71 (in German).
5. Owens, D.R. New horizons: Alternative routes for insulin therapy. Nat Rev, Drug Disc 2002, 1: 529-40.
6. Stratton, I.M., Adler, A.I., Neil, H.A. et al. Association of glycaemia with macro vascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000, 321: 405-12.
7. Nathan, D.M., Lachin, J., Cleary, P. et al. Intensive diabetes therapy and carotid intima - Media thickness in type 1 diabetes mellitus. N Engl J Med 2003, 348: 2294-303.
8. Wall, D.A. Pulmonary absorption of peptides and proteins. Drug Deliv 1995, 2: 1-20.
9. Byron, P.R., Patton, J.S. Drug delivery via the respiratory tract. J Aerosol Med 1994, 7: 49-75.
10. Exubera® U.S. prescribing information: http://www.fda.gov/cder/foi/ label/2006/021868lbl.pdf.
11. Patton, J.S., Bukar, J.G., Eldon, M.A. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004, 43: 781-801.
12. Heyder, J., Gebhart, J., Rudolf, G., Schiller, C.E., Stahlhofen, W. Deposition of particles in the human respiratory tract in the size range 0.005-15 m. J Aerosol Sci 1986, 17: 811-25.
13. White, S., Bennett, D.B., Cheu, S. et al. Exubera®: Pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther 2005, 7: 896-906.
14. Rosenstock, J., Zinman, B., Murphy, L.J. et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes. Ann Intern Med 2005, 143: 549-58.
15. Finch, G.L. Nonclinical pharmacology and safety studies of insulin administered to the respiratory tract. In: Salem, H., Katz, S.A. (Eds.). Inhalation Toxicology. CRC Press, 2nd edition; London 2005, 603-14.
16. Rave, K., Bott, S., Heinemann, L. et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005, 28: 1077-82.
17. Henry, R., Mudaliar, S., Fryburg, D.A. et al. Within-subject variability of inhaled insulin (Exubera®) versus subcutaneous regular insulin in elderly obese patients with type 2 diabetes mellitus. Diabetes 2003, 52 (Suppl. 1): A105.
18. Becker, R.H.A., Sha, S., Frick, A.D., Fountaine, R.J. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 2006, 29: 277-82.
19. Skyler, J.S., Cefalu, W.T., Kourides, I.A. et al. Efficacy of human inhaled insulin in type 1 diabetes mellitus: A randomized proof-of-concept study. Lancet 2001, 357: 331-5.
20. Quattrin, T.A., Belanger, A., Bohannon, J.H.V., Schwartz, S.L. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care 2004, 27: 2622-7.
21. Skyler, J.S., Weinstock, R.S., Raskin, P. et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: A 6-month, randomized, comparative trial. Diabetes Care 2005, 28: 1630-5.
22. Dumas, R., England, R.D., Riese, R.J., Teeter, J.G.; Exubera® Phase 3 Study Group. Exubera® is well tolerated and achieves tight glycemic control in patients with type 1 diabetes. Diabetes 2005, 54 (1 Suppl.): A87.
23. Cefalu, W.T., Skyler, J.S., Kourides, I.A. et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001, 134: 203-7.
24. Cefalu, W.T. Inhaled insulin: A proof-of-concept study. Ann Intern Med 2001, 134: 795.
25. Weiss, S.R., Cheng, S.L., Kourides, I.A., Gelfand, R.A., Landschulz, W.H. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents. Arch Intern Med 2003, 163: 2277-82.
26. Hollander, P.A., Blonde, L., Rowe, R. et al. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care 2004, 27: 2356-62.
27. Barnett, A.H.; Exubera® Phase 2 Study Group. Efficacy and one-year pulmonary safety of inhaled insulin (Exubera®) as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled on oral agent monotherapy. Diabetes 2004, 53 (2 Suppl.): A107.
28. DeFronzo, R.A., Bergenstal, R.M., Cefalu, W.T. et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. Diabetes Care 2005, 28: 1922-8.
29. Philips, L.S., Grunberger, G., Miller, E., Patwardhan, R., Rappaport, E.B., Salzman, A.; Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001, 24: 308-15.
30. Skyler, J.S.; Inhaled Insulin Phase 2 Study Group. Long-term sustained efficacy and safety of inhaled insulin after 4 years of continuous therapy. Diabetologia 2004, 47 (Suppl. 1): A311.
31. Dreyer, M.; Exubera® Phase 3 Study Group. Efficacy and 2-year pulmonary safety data of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled with oral monotherapy. Diabetologia 2004, 47 (1 Suppl.): A44.
32. Riese, R.J., Teeter, J.G., England, R.D. Inhaled insulin does not induce immediate airway responsiveness in patients with type 1 diabetes mellitus. Eur Respir J 2005, 26 (Suppl. 49): 582S.
33. Brain, J.D. Unlocking the opportunity of tight glycaemic control. Inhaled insulin: Safety. Diabetes Obes Metab 2005, 7 (Suppl. 1): S14-8.
34. Heise, T., Bott, S., Tusek, S., Stephan, J.A. et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: A prospective randomized pharmacodynamic study. Diabetes Care 2005, 28: 2161-9.
35. Fineberg, S.E., Kawabata, T., Finco-Kent, D., Liu, C., Krasner, A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera®) trials and a two-year extension trial. J Clin Endocrinol Metab 2005, 90: 3287-94.
36. Saaddine, J.B., Engelgau, M.M., Beckles, G.L., Gregg, E.W., Thompson, T.J., Venkat Narayan, K.M.V. A diabetes report card for the United States: Quality of care in the 1990s. Ann Intern Med 2002, 136: 565-74.
37. Gerber, R.A., Cappelleri, J.C., Kourides, I.A., Gelfand, R.A. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: A randomized controlled trial. Diabetes Care 2001, 24: 1556-9.
38. Cappelleri, J.C., Cefalu, W.T., Rosenstock, J., Kourides, I.A., Gerber, R.A. Treatment satisfaction in type 2 diabetes: A comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002, 24: 552-64.
39. Rosenstock, J., Cappelleri, J.C., Bounder, B., Gerber, R.A. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera®) in patients with type 1 or type 2 diabetes. Diabetes Care 2004, 27: 1318-23.
40. Testa, M.A., Turner, R.R., Hayes, J.F., Simonson, D.C. Patient satisfaction and quality of life in type 1 diabetes: A randomized trial of injectable vs. inhaled insulin. Diabetes 2001, 50 (Suppl. 2): A45.
41. Testa, M.A., Turner, R.R., Hayes, J.F., Simonson, D.C. Intensive therapy and patient satisfaction in type 1 diabetes: A randomized trial of injected vs. inhaled insulin. Diabetologia 2001, 44 (Suppl. 1): A4.
42. Testa, M.A., Turner, R.R., Hayes, J.F., Simonson, D.C. Patient satisfaction with insulin therapy in type 2 diabetes: A randomized trial of injectable vs. inhaled insulin. Diabetes 2002, 51 (Suppl. 2): A135.
43. Simonson, D.C., Hayes, J.F., Turner, R.R., Testa, M.A. Treatment satisfaction and preferences in type 2 diabetes: A randomized trial of oral agents vs. inhaled insulin. Diabetes 2001, 50 (Suppl. 2): A131.
44. Freemantle, N., Blonde, L., Duhot, D. et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005, 28: 427-8.
45. Testa, M.A., Turner, R.R., Hayes, J.F., Scranton, R.E., Simonson, D.C. An international trial of sulfonylurea plus either metformin or inhaled insulin: Impact on quality of life and treatment satisfaction. Diabetologia 2004, 47 (Suppl. 1): A5.
46. Simonson, D.C., Turner, R.R., Hayes, J.F., Scranton, R.E., Testa, M.A. Improving quality of life in type 2 diabetes when inhaled insulin is added after failure on metformin: A multicenter, international trial. Diabetologia 2004, 47 (Suppl. 1): A311.
47. Royle, P., Waugh, N., McAuley, L., McIntyre, L., Thomas, S. Inhaled insulin in diabetes mellitus. Cochrane Database of Systematic Reviews 2003, Issue 4., Art. No.: CD003890.pub2. DOI: 10.1002/14651858.
48. Hauber, A.B., Johnson, F.R., Sauriol, L., Lescrauwaet, B. Risking health to avoid injections: Preferences of Canadians with type 2 diabetes. Diabetes Care 2005, 28: 2243-5.
49. Peyrot, M., Rubin, R.R., Lauritzen, T. et al.; The International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005, 28: 2673-9.
50. Korytkowski, M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002, 26 (Suppl. 3): S18-24.
51. Zambanini, A., Newson, R.B., Maisey, M., Feher, M.D. Injection-related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999, 46: 239-46.